ALNY Alnylam Pharmaceuticals Inc

Price (delayed)

$191.16

Market cap

$22.72B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.59

Enterprise value

$22.73B

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is ...

Highlights
The company's revenue has surged by 99% YoY and by 20% QoQ
The gross profit has soared by 94% YoY and by 21% from the previous quarter
The debt has soared by 142% YoY and by 47% from the previous quarter
The equity has contracted by 39% YoY and by 8% from the previous quarter

Key stats

What are the main financial stats of ALNY
Market
Shares outstanding
118.85M
Market cap
$22.72B
Enterprise value
$22.73B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
26.33
Price to sales (P/S)
32.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.07
Earnings
Revenue
$687.53M
EBIT
-$760.48M
EBITDA
-$675.8M
Free cash flow
-$653.5M
Per share
EPS
-$7.59
Free cash flow per share
-$5.55
Book value per share
$7.26
Revenue per share
$5.84
TBVPS
$29.8
Balance sheet
Total assets
$3.51B
Total liabilities
$2.66B
Debt
$761.07M
Equity
$853.36M
Working capital
$2.17B
Liquidity
Debt to equity
0.89
Current ratio
4.91
Quick ratio
3.69
Net debt/EBITDA
-0.02
Margins
EBITDA margin
-98.3%
Gross margin
83.3%
Net margin
-129%
Operating margin
-109.4%
Efficiency
Return on assets
-26.3%
Return on equity
-88.4%
Return on invested capital
-26.7%
Return on capital employed
-25.7%
Return on sales
-110.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALNY stock price

How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
-3.31%
1 week
-6.21%
1 month
-1.39%
1 year
50.73%
YTD
47.08%
QTD
1.24%

Financial performance

How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$687.53M
Gross profit
$572.9M
Operating income
-$751.84M
Net income
-$886.68M
Gross margin
83.3%
Net margin
-129%
The company's revenue has surged by 99% YoY and by 20% QoQ
The gross profit has soared by 94% YoY and by 21% from the previous quarter
The company's operating margin has surged by 59% YoY and by 22% QoQ
The net margin has grown by 47% YoY and by 16% from the previous quarter

Growth

What is Alnylam Pharmaceuticals's growth rate over time

Valuation

What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
26.33
P/S
32.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.07
ALNY's price to book (P/B) is 189% more than its 5-year quarterly average of 9.1 and 50% more than its last 4 quarters average of 17.5
The equity has contracted by 39% YoY and by 8% from the previous quarter
The company's revenue has surged by 99% YoY and by 20% QoQ
ALNY's price to sales (P/S) is 58% lower than its 5-year quarterly average of 77.4

Efficiency

How efficient is Alnylam Pharmaceuticals business performance
ALNY's return on sales has surged by 53% year-on-year and by 17% since the previous quarter
The ROE has plunged by 51% YoY and by 15% from the previous quarter
ALNY's return on invested capital is up by 36% year-on-year
The return on assets has increased by 18% year-on-year

Dividends

What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNY.

Financial health

How did Alnylam Pharmaceuticals financials performed over time
The total assets is 32% more than the total liabilities
The company's total liabilities rose by 35% YoY and by 14% QoQ
The company's quick ratio fell by 29% YoY
The debt is 11% less than the equity
The debt has soared by 142% YoY and by 47% from the previous quarter
Alnylam Pharmaceuticals's debt to equity has soared by 59% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.